RetinalGenix Technologies Inc. has announced a strategic partnership with LabCorp, one of the nation's largest laboratory services organizations, to support the nationwide rollout of its innovative DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform. The collaboration aims to revolutionize early disease detection by combining genetic testing with high-resolution retinal imaging to identify both ocular and systemic diseases.
Platform Integration and Testing Process
Through this partnership, patients can visit any USA-based LabCorp location to undergo comprehensive testing that includes collection and analysis of blood, tears, nasal secretions, and saliva. The samples are analyzed using proprietary algorithms developed by RetinalGenix's DNA/RNA GPS analysis platform, which correlates genetic and retinal biomarkers to establish new standards for early detection of various health conditions.
The testing process allows patients to maintain full control of their health records, which remain anonymous and confidential. Appointments and test orders are managed through the RetinalGenix online platform, with results securely released to patients upon validation of payment at their chosen LabCorp center.
Clinical Leadership and Scientific Vision
Dr. Taimour Langaee, PhD, who oversees the company's DNA/GPS genotyping/sequencing data processing, genetic and pharmacogenomics data analyses, and clinical genetic association studies between eye diseases and genetic variations, emphasized the platform's potential impact. "I am excited that this creates great opportunities to further expand our knowledge about the important role of genetics and precision medicine in eye diseases, affecting millions of people and the potential to discover novel genetic variants and treatments," Dr. Langaee stated.
Dr. Larry Perich, DO, Advisor for the DNA/RNA/GPS program, highlighted the expanding diagnostic capabilities: "As the database of disease-associated biomarkers expands, we expect the value of these platforms for diagnosing both ocular and systemic diseases continues to grow, promising improved outcomes and more accessible care."
Cost-Effective Healthcare Solution
The platform is designed to address rising healthcare costs by providing a more accessible alternative to expensive diagnostic procedures. According to Dr. Jerry Katzman, MD, RetinalGenix Technologies CEO, "The cost of healthcare is enormous, and patient access is critical. This cost-effective methodology aims to reduce reliance on expensive diagnostic procedures such as MRIs, CT scans, PET Scans, echocardiograms to name a few, helping to alleviate the financial burden on both patients and the healthcare system."
The company is actively collaborating with regulators to establish CPT codes, which should further lower healthcare costs and improve access to necessary evaluations while streamlining the already overburdened patient assessment process.
Future Expansion Plans
RetinalGenix plans to introduce high-resolution retinal imaging as a value-added service at various locations in the near future. The integration of high-resolution imaging is expected to further boost diagnostic accuracy, allowing even general practitioners and standard eye clinics to assist in patient mass screening.
These innovations are specifically designed to make screening more accessible, cost-effective, and capable of detecting disease at earlier, more treatable stages. The platform's focus extends beyond ocular conditions to include neurodegenerative, cardiovascular, vascular, and metabolic systems, as well as diabetic conditions, Alzheimer's disease, and Parkinson's disease.
Company Background
RetinalGenix Technologies is a developmental-stage company focused on ophthalmic screening, monitoring, pharmacogenetic mapping, and repurposed drug development. The company's proprietary technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases. RetinalGenix is also developing therapeutic drugs for dry age-related macular degeneration and Alzheimer's disease/dementia.
